SEC Form 4 · accession 0001012975-18-001198
Twist Bioscience Corp · TWST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Robert Nelsen
10% Owner
Clinton Bybee
10% Owner
ARCH Venture Fund VII, L.P.
10% Owner
ARCH Venture Partners VII, LLC
10% Owner
ARCH Venture Partners VII, L.P.
10% Owner
ARCH Venture Partners VIII, LLC
10% Owner
ARCH Venture Fund VIII Overage, L.P.
10% Owner
Period of report
Nov 2, 2018
Accepted (ET)
Nov 6, 2018 · 4:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581280
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Nov 2, 2018 | C | 1,182,645 | — | A | 1,182,645 | I | See footnote |
| Common StockF1,F2,F3 | Nov 2, 2018 | C | 718,275 | — | A | 1,900,920 | I | See footnote |
| Common StockF1,F2,F3 | Nov 2, 2018 | C | 266,776 | — | A | 2,167,696 | I | See footnote |
| Common StockF1,F2,F3 | Nov 2, 2018 | C | 224,726 | — | A | 2,392,422 | I | See footnote |
| Common StockF4,F2,F3 | Nov 2, 2018 | P | 15,000 | $14.00 | A | 2,407,422 | I | See footnote |
| Common StockF1,F5,F3 | Nov 2, 2018 | C | 894,146 | — | A | 894,146 | I | See footnote |
| Common StockF4,F5,F3 | Nov 2, 2018 | P | 60,000 | $14.00 | A | 954,146 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred StockF1,F2,F3,F6 | — | Nov 2, 2018 | C | 1,182,645 | D | — | — | Common Stock | 1,182,645 | 0 | I |
| Series B Preferred StockF1,F2,F3,F6 | — | Nov 2, 2018 | C | 718,275 | D | — | — | Common Stock | 718,275 | 0 | I |
| Series C Preferred StockF1,F2,F3,F6 | — | Nov 2, 2018 | C | 266,776 | D | — | — | Common Stock | 266,776 | 0 | I |
| Series D Preferred StockF1,F2,F3,F6 | — | Nov 2, 2018 | C | 224,726 | D | — | — | Common Stock | 224,726 | 0 | I |
| Series D Preferred StockF1,F5,F3,F6 | — | Nov 2, 2018 | C | 894,146 | D | — | — | Common Stock | 894,146 | 0 | I |
Explanation of responses
- F1Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis.
- F2The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- F3Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- F4Reflects shares purchased in the Issuer's initial public offering.
- F5The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- F6The expiration date is not relevant to the conversion of these securities.